ESGBERT/base_data · Datasets at Hugging Face

sentence stringlengths 1 23.5k ⌀
Effectively, an Ansell team interacts with key stakeholders on a quarterly basis either from an executive leadership and/or Board perspective.
That is, the biannual earnings release investor circuit with CEO & CFO enables direct accessibility and then separately investor and proxy advisor circuits are conducted with the Chairman and Deputy Chairman during the fiscal year.
Lastly, the Investor Relations team holds upwards +conference calls with existing and potential shareholders.
By consistently delivering on our promises and commitments, we aim to gain market share and grow profitability, which in turn will improve shareholder value.
We must also deliver investor engagement by being a company that our shareholders can be proud to own; one with excellent environmental sustainability, labour relations, employee engagement, workplace safety and business ethics.
Ansell is committed to transparent engagement with its investors and is an active member of the Australian Investor Relations Association.
* Total Shareholder Return is the cumulative finance return that an investor received from holding shares in Ansell, assuming dividends paid are reinvested in Ansell shares.
Financial Disclosures This year marked the commencement of our journey to disclose material climate change-related financial risks regarding the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).
TCFD is receiving significant support around the world to make markets more efficient by developing consistent climate-related disclosure to better inform investors, lenders, insurers and other stakeholders.
to register their support of the recommendations of the TCFD.
Reporting and Disclosure Ansell understands that investor expectations around reporting and disclosure of material issues continue to evolve.
We are committed to continuous review and improvement of our own disclosure practices to ensure we continue to meet emerging expectations.
To that end, in FYfor reporting against the GRI Standards, which we plan to complete for our FY20 results.
As detailed through-out this report, we are also elevating our ambition on the assessment and disclosure in specific areas of regulatory and investor interest, such as modern slavery and climate-related financial risks.
Responsibility Report We are thankful to our colleagues across the company whose efforts carried us this far on our responsibility journey.
The global responsibility goals are a challenging but attainable next step.
We remain committed to being transparent and sharing our progress along the way.
This is an important new stage for our company and we welcome your feedback as we strive to advance our new goals.
As we publish this report in April continues to face the COVID-19 pandemic — a public health crisis unlike any experienced in our lifetimes.
We are proud that Regeneron has risen to this challenge with characteristic drive and scientific innovation.
We are broadly applying the resources and talent within our company to identify potentially effective therapies and make them available, while at the same time rallying to support the needs of our communities, particularly in our home state of New York.
Our science-driven culture and commitment to ‘Doing Well by Doing Good’ has inspired our company for over years — and continues to inspire our fight against COVID19.
We are proud that these attributes have always defined how we run our business and underpin our responsibility focus areas: 1.
Build sustainable communities In our approach to responsibility.
We discovered and developed a potential treatment for Ebola virus infection, a major public health advance with important implications for current and future outbreaks.
We are now applying the same core technologies to our COVID-development efforts.
We also continued to make significant investments to attract and retain top talent and sustain our culture of integrity.
In addition to our ongoing $Science Talent Search, the nation’s oldest and most prestigious high school science competition, we opened a new experiential program for middle- and high-school students, the Regeneron DNA Learning Center, a program of Cold Spring Harbor Laboratory.
We also became the new title sponsors of the International Science and Engineering Fair (ISEF), the world’s largest pre-college science and engineering competition.
Looking to the future, in responsibility goals, which span across our three strategic focus areas.
We are pleased to share these goals publicly for the first time in this Report.
The goals are accompanied by ambitious environmental targets.
We are challenging ourselves to establish sciencebased targets for Scope by 2023 and to be 50 percent renewable by 2025 and 100 percent renewable by 2035.
In addition, the targets formalize our ambition to divert from landfill.
CHAIRMAN OF THE BOARD LEONARD S. SCHLEIFER, M.D., PH.D.
Regeneron is a great place to work in our annual engagement survey out of 1.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Founded and led for over ability to repeatedly and consistently translate science into medicine has led to seven U.S. Food and Drug Administration (FDA)-approved treatments and numerous product candidates in clinical development, all of which were homegrown in our laboratories.
Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
R&D INVESTMENT¹REVENUE¹ $2017 $6.711B 2018 $7.863B 2019 $2.075B 2017 $3.037B 2019 $2.186B 2018 1.
As reported in Regeneron’s Annual Report on Form 10-K for the year ended December 31, 2019.
In the second quarter of certain reimbursements and other payments for products developed and commercialized with collaborators.
These changes were made effective January 1, 2020 and have also been applied retrospectively.
There is no impact from these changes to net income or net income per share.
We continue to operate Regeneron with the long-term outlook required to turn rigorous scientific research into important new medicines.
We believe long-term leadership provides continuity and value to an innovative business.
We have been led for three decades by our founders, Len Schleifer and George Yancopoulos, who have established a consistent vision and culture that sets us apart.
Our business is built on our deep scientific and technological capabilities, which drive our research and development, clinical and production efforts.
Running the business responsibly has always been at the heart of how we operate, and it impacts every part of our business, from diseases we choose to research to how we price our medicines.
We are motivated by our mission of repeatedly bringing important new medicines to people living with serious disease.
Our investments and unique proprietary technologies are designed to accelerate the average time from discovery to drug approval and improve success rates so that we can reach patients faster.
We continue to reinvest a significant portion of revenue — an average of $over the past three years — back into our R&D efforts.
We are proud that as a result of this focus on R&D, all of our approved medicines and all the product candidates in our clinical pipeline were homegrown in our own labs.
Production and supply With facilities in Rensselaer, New York and Limerick, Ireland, our award-winning Industrial Operations and Product Supply (IOPS) team is responsible for the manufacturing, distribution and quality assurance of a wide range of our biologic medicines, including our approved antibodies and those involved in clinical studies.
Commercialization and access Our medicines only matter if patients in need can access and afford them.
We seek input from a variety of stakeholders to determine fair pricing, and work with insurers and physicians to improve treatment access.
We provide patient support services to help patients through their treatment journey and support organizations that help people touched by serious diseases.
Collaborations Collaborations play a vital role in delivering on our mission to use innovative science to bring new medicines to people with serious diseases.
Our collaborations with government entities and large pharmaceutical companies such as Bayer, Teva and Sanofi support our ability to develop our medicines globally and expand access for patients around the world.
We also pursue collaborations with academic institutions and emerging biopharma companies to continue pushing our science and technological capabilities to the absolute bleeding edge of biomedical innovation.
Additionally, we share Regeneron’s science and technologies with collaborators like Decibel, Bluebird and Zoetis so that we can extend our impact to many more fields of medicine than we could reach on our own.
Developed and commercialized under global collaboration with Sanofi until April 1, 2020.
Effective April rights to Praluent; Sanofi has sole rights to Praluent outside the U.S.; and Sanofi pays Regeneron a 5% royalty on Praluent net product sales outside the U.S. 3.
Since our founding more than Regeneron has grown into a leading science and technology company that delivers life-changing medicines to patients in need.
In that time, we have experienced tremendous growth in the size of our workforce — nearly alone — and the composition of our workforce has changed in tandem.
Recognizing the impact of such rapid change, in we rolled out The Regeneron Way, the company’s refreshed values and behaviors that define who we are, what we stand for and how we work together.
The Regeneron Way puts into words our special culture that has fueled our innovation from the start.
The Regeneron Way Our mission is to repeatedly bring important new medicines to patients with serious diseases. LEAD WITH SCIENCE Science drives our business, and passion drives our science.
Well By Doing Good’ remains central to our approach to responsibility.
The Board of Director’s Corporate Governance and Compliance Committee has formal oversight of corporate responsibility and meets annually to review progress against our responsibility strategy.
which builds on our legacy of environmental sustainability reporting.
GLOBAL TRANSPARENCY AND REPORTING We report on data and activities related to our responsibility strategy for our fiscal January 1 to December 31, 2019 (except where indicated otherwise) and spanning across our global operations.
In addition to this report, we disclose select environmental, social and governance (ESG) information to relevant third parties that produce ESG ratings and rankings, including CDP, a global environmental disclosure non-profit organization.
For the first time, our disclosures with the Sustainability Accounting Standards Board (SASB) framework.
The three focus areas inform the structure of this report and guide our strategy.
Use the power of science to discover and advance important new medicines while continuing to make substantial investments into R&D.
• Set fair, value-based prices for our medicines and break down barriers to patient access.
• Support organizations that offer disease prevention, diagnosis and treatment for people touched by serious diseases.
Cultivate a leading workplace experience that is rooted in our unique science-driven culture.
• Increase representation of qualified diverse individuals in leadership and foster inclusion across our organization.
• Be vigilant in ensuring integrity remains at the core of how we operate.
• Implement continuous improvements to uphold our high-quality, safe and reliable product supply.
• Make Regeneron the safest part of people’s day by focusing on prevention in our drive towards zero incidents.
• Drive employee volunteer levels above national standards.
* See next page for specific environmental targets.
By landfill status at all Regeneron sites.¹ By 2021, compost food waste at all sites with more than 2,000 employees.
By suppliers, representing more than 50% of spend, to gather and report relevant Scope 3 greenhouse gas (GHG) emissions data.
By increase our plastic recycling and reduce hazardous waste generation.
By per square meter by 30% based on 2016 peak baseline.
By 100% of our electricity consumption with electricity from certified renewable energy sources.
The United Nations Sustainable Development Goals (SDGs) represent a global agenda to address the most pressing problems facing our world today.
Quality EducationQuality Education Through our efforts to improve the lives of people with serious diseases, we are making meaningful contributions to the reduction of premature mortality from non-communicable diseases (SDG Target supporting the R&D of medicines for communicable and non-communicable diseases that primarily affect developing countries (SDG Target 3.B).
Offering internship, apprenticeship and co-op opportunities at Regeneron (page Through our commitment to provide STEM (Science, Technology, Engineering and Math) experiences to 2.5 million students, we aim to help ensure equal access for all women and men to affordable education (SDG (SDG Target 4.3)Target 4.3) and increase the number of youth and adults who have relevant skills for employment, decent jobs and entrepreneurship (SDG Target 4.4)(SDG Target 4.4).
Gender Equality Through our efforts to foster a diverse and inclusive workplace and provide engaging STEM experiences, we are trying to do our part to end all forms of discrimination against all women and girls (SDG Target women’s full and effective participation and equal opportunities for leadership at all levels of decisionmaking (SDG Target 5.5).
Partnerships for the GoalsPartnerships for the Goals Regeneron’s commitment to enhance and share our responsible waste management efforts helps advance sustainable management and efficient use of natural resources (Target prevention, reduction, recycling and reuse (Target 12.5) and encourage companies to adopt sustainable practices and to integrate sustainability information into their reporting cycle (Target 12.6).
Collaboration is essential to achieving Regeneron’s mission to repeatedly bring important new medicines to people with serious diseases.
We engage a range of Regeneron stakeholders on responsibility topics throughout the year.
As a science-focused company, we operate Regeneron with the long-term outlook required to turn rigorous scientific research into important new medicines.
All of our approved medicines and all of the product candidates in our clinical pipeline are homegrown — discovered in Regeneron’s labs using our industry-leading, proprietary technologies.

Effectively, an Ansell team interacts with key stakeholders on a quarterly basis either from an executive leadership and/or Board perspective.

That is, the biannual earnings release investor circuit with CEO & CFO enables direct accessibility and then separately investor and proxy advisor circuits are conducted with the Chairman and Deputy Chairman during the fiscal year.

Lastly, the Investor Relations team holds upwards +conference calls with existing and potential shareholders.

By consistently delivering on our promises and commitments, we aim to gain market share and grow profitability, which in turn will improve shareholder value.

We must also deliver investor engagement by being a company that our shareholders can be proud to own; one with excellent environmental sustainability, labour relations, employee engagement, workplace safety and business ethics.

Ansell is committed to transparent engagement with its investors and is an active member of the Australian Investor Relations Association.

* Total Shareholder Return is the cumulative finance return that an investor received from holding shares in Ansell, assuming dividends paid are reinvested in Ansell shares.

Financial Disclosures This year marked the commencement of our journey to disclose material climate change-related financial risks regarding the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).

TCFD is receiving significant support around the world to make markets more efficient by developing consistent climate-related disclosure to better inform investors, lenders, insurers and other stakeholders.

to register their support of the recommendations of the TCFD.

Reporting and Disclosure Ansell understands that investor expectations around reporting and disclosure of material issues continue to evolve.

We are committed to continuous review and improvement of our own disclosure practices to ensure we continue to meet emerging expectations.

To that end, in FYfor reporting against the GRI Standards, which we plan to complete for our FY20 results.

As detailed through-out this report, we are also elevating our ambition on the assessment and disclosure in specific areas of regulatory and investor interest, such as modern slavery and climate-related financial risks.

Responsibility Report We are thankful to our colleagues across the company whose efforts carried us this far on our responsibility journey.

The global responsibility goals are a challenging but attainable next step.

We remain committed to being transparent and sharing our progress along the way.

This is an important new stage for our company and we welcome your feedback as we strive to advance our new goals.

As we publish this report in April continues to face the COVID-19 pandemic — a public health crisis unlike any experienced in our lifetimes.

We are proud that Regeneron has risen to this challenge with characteristic drive and scientific innovation.

We are broadly applying the resources and talent within our company to identify potentially effective therapies and make them available, while at the same time rallying to support the needs of our communities, particularly in our home state of New York.

Our science-driven culture and commitment to ‘Doing Well by Doing Good’ has inspired our company for over years — and continues to inspire our fight against COVID19.

We are proud that these attributes have always defined how we run our business and underpin our responsibility focus areas: 1.

Build sustainable communities In our approach to responsibility.

We discovered and developed a potential treatment for Ebola virus infection, a major public health advance with important implications for current and future outbreaks.

We are now applying the same core technologies to our COVID-development efforts.

We also continued to make significant investments to attract and retain top talent and sustain our culture of integrity.

In addition to our ongoing $Science Talent Search, the nation’s oldest and most prestigious high school science competition, we opened a new experiential program for middle- and high-school students, the Regeneron DNA Learning Center, a program of Cold Spring Harbor Laboratory.

We also became the new title sponsors of the International Science and Engineering Fair (ISEF), the world’s largest pre-college science and engineering competition.

Looking to the future, in responsibility goals, which span across our three strategic focus areas.

We are pleased to share these goals publicly for the first time in this Report.

The goals are accompanied by ambitious environmental targets.

We are challenging ourselves to establish sciencebased targets for Scope by 2023 and to be 50 percent renewable by 2025 and 100 percent renewable by 2035.

In addition, the targets formalize our ambition to divert from landfill.

CHAIRMAN OF THE BOARD LEONARD S. SCHLEIFER, M.D., PH.D.

Regeneron is a great place to work in our annual engagement survey out of 1.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Founded and led for over ability to repeatedly and consistently translate science into medicine has led to seven U.S. Food and Drug Administration (FDA)-approved treatments and numerous product candidates in clinical development, all of which were homegrown in our laboratories.

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

R&D INVESTMENT¹REVENUE¹ $2017 $6.711B 2018 $7.863B 2019 $2.075B 2017 $3.037B 2019 $2.186B 2018 1.

As reported in Regeneron’s Annual Report on Form 10-K for the year ended December 31, 2019.

In the second quarter of certain reimbursements and other payments for products developed and commercialized with collaborators.

These changes were made effective January 1, 2020 and have also been applied retrospectively.

There is no impact from these changes to net income or net income per share.

We continue to operate Regeneron with the long-term outlook required to turn rigorous scientific research into important new medicines.

We believe long-term leadership provides continuity and value to an innovative business.

We have been led for three decades by our founders, Len Schleifer and George Yancopoulos, who have established a consistent vision and culture that sets us apart.

Our business is built on our deep scientific and technological capabilities, which drive our research and development, clinical and production efforts.

Running the business responsibly has always been at the heart of how we operate, and it impacts every part of our business, from diseases we choose to research to how we price our medicines.

We are motivated by our mission of repeatedly bringing important new medicines to people living with serious disease.

Our investments and unique proprietary technologies are designed to accelerate the average time from discovery to drug approval and improve success rates so that we can reach patients faster.

We continue to reinvest a significant portion of revenue — an average of $over the past three years — back into our R&D efforts.

We are proud that as a result of this focus on R&D, all of our approved medicines and all the product candidates in our clinical pipeline were homegrown in our own labs.

Production and supply With facilities in Rensselaer, New York and Limerick, Ireland, our award-winning Industrial Operations and Product Supply (IOPS) team is responsible for the manufacturing, distribution and quality assurance of a wide range of our biologic medicines, including our approved antibodies and those involved in clinical studies.

Commercialization and access Our medicines only matter if patients in need can access and afford them.

We seek input from a variety of stakeholders to determine fair pricing, and work with insurers and physicians to improve treatment access.

We provide patient support services to help patients through their treatment journey and support organizations that help people touched by serious diseases.

Collaborations Collaborations play a vital role in delivering on our mission to use innovative science to bring new medicines to people with serious diseases.

Our collaborations with government entities and large pharmaceutical companies such as Bayer, Teva and Sanofi support our ability to develop our medicines globally and expand access for patients around the world.

We also pursue collaborations with academic institutions and emerging biopharma companies to continue pushing our science and technological capabilities to the absolute bleeding edge of biomedical innovation.

Additionally, we share Regeneron’s science and technologies with collaborators like Decibel, Bluebird and Zoetis so that we can extend our impact to many more fields of medicine than we could reach on our own.

Developed and commercialized under global collaboration with Sanofi until April 1, 2020.

Effective April rights to Praluent; Sanofi has sole rights to Praluent outside the U.S.; and Sanofi pays Regeneron a 5% royalty on Praluent net product sales outside the U.S. 3.

Since our founding more than Regeneron has grown into a leading science and technology company that delivers life-changing medicines to patients in need.

In that time, we have experienced tremendous growth in the size of our workforce — nearly alone — and the composition of our workforce has changed in tandem.

Recognizing the impact of such rapid change, in we rolled out The Regeneron Way, the company’s refreshed values and behaviors that define who we are, what we stand for and how we work together.

The Regeneron Way puts into words our special culture that has fueled our innovation from the start.

The Regeneron Way Our mission is to repeatedly bring important new medicines to patients with serious diseases. LEAD WITH SCIENCE Science drives our business, and passion drives our science.

Well By Doing Good’ remains central to our approach to responsibility.

The Board of Director’s Corporate Governance and Compliance Committee has formal oversight of corporate responsibility and meets annually to review progress against our responsibility strategy.

which builds on our legacy of environmental sustainability reporting.

GLOBAL TRANSPARENCY AND REPORTING We report on data and activities related to our responsibility strategy for our fiscal January 1 to December 31, 2019 (except where indicated otherwise) and spanning across our global operations.

In addition to this report, we disclose select environmental, social and governance (ESG) information to relevant third parties that produce ESG ratings and rankings, including CDP, a global environmental disclosure non-profit organization.

For the first time, our disclosures with the Sustainability Accounting Standards Board (SASB) framework.

The three focus areas inform the structure of this report and guide our strategy.

Use the power of science to discover and advance important new medicines while continuing to make substantial investments into R&D.

• Set fair, value-based prices for our medicines and break down barriers to patient access.

• Support organizations that offer disease prevention, diagnosis and treatment for people touched by serious diseases.

Cultivate a leading workplace experience that is rooted in our unique science-driven culture.

• Increase representation of qualified diverse individuals in leadership and foster inclusion across our organization.

• Be vigilant in ensuring integrity remains at the core of how we operate.

• Implement continuous improvements to uphold our high-quality, safe and reliable product supply.

• Make Regeneron the safest part of people’s day by focusing on prevention in our drive towards zero incidents.

• Drive employee volunteer levels above national standards.

* See next page for specific environmental targets.

By landfill status at all Regeneron sites.¹ By 2021, compost food waste at all sites with more than 2,000 employees.

By suppliers, representing more than 50% of spend, to gather and report relevant Scope 3 greenhouse gas (GHG) emissions data.

By increase our plastic recycling and reduce hazardous waste generation.

By per square meter by 30% based on 2016 peak baseline.

By 100% of our electricity consumption with electricity from certified renewable energy sources.

The United Nations Sustainable Development Goals (SDGs) represent a global agenda to address the most pressing problems facing our world today.

Quality EducationQuality Education Through our efforts to improve the lives of people with serious diseases, we are making meaningful contributions to the reduction of premature mortality from non-communicable diseases (SDG Target supporting the R&D of medicines for communicable and non-communicable diseases that primarily affect developing countries (SDG Target 3.B).

Offering internship, apprenticeship and co-op opportunities at Regeneron (page Through our commitment to provide STEM (Science, Technology, Engineering and Math) experiences to 2.5 million students, we aim to help ensure equal access for all women and men to affordable education (SDG (SDG Target 4.3)Target 4.3) and increase the number of youth and adults who have relevant skills for employment, decent jobs and entrepreneurship (SDG Target 4.4)(SDG Target 4.4).

Gender Equality Through our efforts to foster a diverse and inclusive workplace and provide engaging STEM experiences, we are trying to do our part to end all forms of discrimination against all women and girls (SDG Target women’s full and effective participation and equal opportunities for leadership at all levels of decisionmaking (SDG Target 5.5).

Partnerships for the GoalsPartnerships for the Goals Regeneron’s commitment to enhance and share our responsible waste management efforts helps advance sustainable management and efficient use of natural resources (Target prevention, reduction, recycling and reuse (Target 12.5) and encourage companies to adopt sustainable practices and to integrate sustainability information into their reporting cycle (Target 12.6).

Collaboration is essential to achieving Regeneron’s mission to repeatedly bring important new medicines to people with serious diseases.

We engage a range of Regeneron stakeholders on responsibility topics throughout the year.

As a science-focused company, we operate Regeneron with the long-term outlook required to turn rigorous scientific research into important new medicines.

All of our approved medicines and all of the product candidates in our clinical pipeline are homegrown — discovered in Regeneron’s labs using our industry-leading, proprietary technologies.